Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Livzon Pharmaceutical Group ( (HK:1513) ) is now available.
Livzon Pharmaceutical Group Inc. has proposed a final ordinary cash dividend of RMB 14.3 per 10 shares for the financial year ended 31 December 2025, with the amount to be paid to Hong Kong shareholders to be translated into Hong Kong dollars at an exchange rate yet to be announced. Key timetable details, including the ex-dividend date, record date, payment date, shareholders’ approval date and withholding tax arrangements, remain pending, leaving investors awaiting further clarification on the precise payout schedule and net distribution.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a Hong Kong–listed pharmaceutical company engaged in the development, manufacturing and sale of medicines and healthcare products. The group serves domestic and international markets and is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard listed-company governance structure.
Average Trading Volume: 774,806
Technical Sentiment Signal: Hold
Current Market Cap: HK$29.76B
Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.